15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Pmv Pharmaceuticals Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $3.00 to $5.00, a moderate spread. The average target of $4.33 sits 216% above the current $1.37. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.29 next quarter toward $-0.97 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Pmv Pharmaceuticals Inc.
As of Sep, 3 of 3 firms rate PMVP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PMVP EPS & revenue forecast
EPS · NEXT QUARTER
$-0.29
Range $-0.36 – $-0.18 · 3 analysts · -14% YoY
Next period, 3 analysts expect Pmv Pharmaceuticals Inc to earn $-0.29 a share (range $-0.36 – $-0.18), versus $-0.34 a year earlier. Full-year consensus is $-1.28, growing to $-0.97 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $5.0M next year.
Top analysts covering Pmv Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PMVP.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$5.00+265.0% to target
Overall win rate
41%
+ Follow
#2
Jeff Jones
Oppenheimer · Rank #247
Buy
$5.00+265.0% to target
Overall win rate
31%
+ Follow
#3
Yaron Werber
TD Cowen
Buy
No targeton PMVP
Coverage
—
+ Follow
#4
AL
Albert Lowe
Craig-Hallum
Buy
$4.00+192.0% to target
Coverage
—
+ Follow
PMVP stock forecast FAQ
What is PMVP's average 12-month price target?+
The 2 analysts with a live target average $4.33 for Pmv Pharmaceuticals Inc over the next 12 months, ranging from a $5.00 high to a $3.00 low.
Is PMVP stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PMVP?+
The Street-high target is $5.00 (HC Wainwright & Co.), and the Street-low is $3.00. The average of all 2 active targets is $4.33.
How many Wall Street analysts cover PMVP?+
3 analysts have an active rating on Pmv Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering PMVP?+
Among analysts who currently cover PMVP, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #199). Their current call is Buy with a $5.00 target.
What is Pmv Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.29 per share (range $-0.36 – $-0.18) across 3 analysts. Full-year EPS is projected at $-1.28, rising to $-0.97 the following year.
How much revenue is Pmv Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $5.0M next year.
Have analysts been upgrading or downgrading PMVP lately?+
As of Sep, 3 of 3 firms rate PMVP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PMVP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
